$1.00 On The Horizon, page-381

Well - of course it could go either way however on balance I thought it was worth the risk today.

Surely if it works as advertised this company is worth multiples of where we are today.

In it for the long term for these reasons:

Investment Highlights

NOVEL ANTIVIRAL PLATFORM

Targeting viroporin proteins with a rapid screening proprietary primary bacterial cell-based platform - a library of over 350 compounds with activity against a range of viruses.

BROAD ANTIVIRAL PIPELINE

Clinical and Preclinical programs in indications with high unmet clinical need or large patient populations such as HIV-1, HCV & Dengue, HBV, Zika & Influenza.

ROBUST CLINICAL VALIDATION

Completed 7 human Clinical Trials with promising safety and efficacy outcomes.

STRONG INTELLECTUAL PROPERTY POSITION

Portfolio of patents and patent applicaTons directed to the Company’s anti-viral drug portfolio.

GLTAH